Nathan downhour interview, Medicare post-PHE update, Drug Watch list and FDA decisions
Prime Client Portal
April 19, 2023
Weekly Prime client digest
In addition to the corporate client emails you receive, provided is a weekly digest that bundles information and reminders for your convenience.  ​​​​​​ 
Interview with Prime's Nathan Downhour
Relevant for all lines of business
Nathan Downhour, Prime's senior vice president of health care services, talks Prime's clinical products and programs, what makes us different from the big three PBMs and more.
Post-PHE: Paxlovid and 90-day transition supply
Medicare
​​​​Included are updates to Prime’s stance on Paxlovid as it relates to Medicare, as well as further guidance from CMS on the 90-day transitions supply.
Drug watch list - April 
Relevant for all lines of business
Prime publishes a monthly drug watch list to proactively communicate to clients the most notable drugs that may significantly affect the populations we serve.
May decisions expected from the FDA 
Relevant for all lines of business
At Prime, we’ve positioned ourselves to best prepare our clients to manage new drugs. In this article, our clinical and trade relations teams outline drugs likely to be approved by the U.S. Food and Drug Administration (FDA).
For feedback or questions on corporate client communications, please contact clientcommunications@primetherapeutics.com.

To access additional Prime client communications and resources, check out the Prime Client Portal. If you don't have access to the portal, contact your IT administrator to request access just as you would to access any Prime application. 
​​​​​​
Share this email
Is this email not displaying correctly?
View it in your browser.
Prime Therapeutics
2900 Ames Crossing Road
Eagan, MN 55121
© Prime Therapeutics LLC  |  PrimeTherapeutics.com  |  Update email preferences  Contact us.